Adeno-associated virus type 2-mediated gene transfer of a short hairpin-RNA targeting human IGFBP-2 suppresses the proliferation and invasion of MDA-MB-468 cells

CHAO GAO¹, RU-SONG ZHANG², NAN ZHENG³ and CHEN WANG³

¹The Center for Clinical Reproductive Medicine, Jiangsu Hospital, Nanjing, Jiangsu 210029; ²The Pathology Department, Nanjing General Hospital of Nanjing Military Command, Nanjing, Jiangsu 210002; ³State Key Laboratory of Chemistry for Life Science & Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing, Jiangsu 210093, P.R. China

Received March 3, 2017; Accepted August 14, 2017

DOI: 10.3892/mmr.2018.8434

Abstract. Adeno-associated virus 2 (AAV2) is prepotent in the biological treatment of breast tumor because of its low pathogenicity and immunogenicity. Our previous study demonstrated that insulin-like growth factor-binding protein 2 (IGFBP-2) was highly expressed in patients with breast metastasis. In the present study, the effects of recombinant AAV2 on the growth and metastasis of breast cancer cells were determined in vitro, and in vivo. rAAV2-ZsGreen-shRNA-scramble and rAAV2-ZsGreen-shRNA-hIGFBP-2 were used to transfect MDA-MB-468, and MCF-10A cells respectively, and observed that these virus could not penetrate the normal human breast epithelia MCF-10A cell line. To investigate the effect of the recombinant virus on chemotherapeutics, paclitaxel was added to MDA-MB-468 cells and it was demonstrated that rAAV2-ZsGreen-shRNA-hIGFBP-2-infected MDA-MB-468 cells were highly chemosensitive to paclitaxel compared with rAAV2-ZsGreen-shRNA-scramble-infected cells. In addition, it was demonstrated that the invasive ability of rAAV2-ZsGreen-shRNA-hIGFBP-2-infected MDA-MB-468 cells was highly impaired compared with the rAAV2-ZsGreen-shRNA-scramble group. In the nude mice xenografts, the rAAV2-ZsGreen-shRNA-hIGFBP-2 injection inhibited tumor growth and Ki-67 expression was significantly downregulated compared with the scramble group. Following IGFBP-2 knockdown using rAAV2-ZsGreen-shRNA-hIGFBP-2, matrix metalloproteinase-2 expression was significantly reduced in tumor tissues compared with that in rAAV2-ZsGreen-shRNA-scramble treated tumor tissues. These findings have provided a direction for the application of novel AAV2-based therapeutics for treating aggressive triple-negative breast cancer types.

Introduction

Serum levels of insulin-like growth factor-binding protein-2 (IGFBP-2) are significantly increased in, and have been correlated with, tumor progression in a number of different cancers, including colon (1), ovarian (2,3), lung (4), and prostate (5,6). In addition, the levels of IGFBP-2 in the serum and tumors of breast cancer patients are significantly elevated (7,8), and tumor IGFBP-2 expression correlates with malignancy (7). IGFBP-2 has also been shown to modulate cell adhesion and migration (9) in an IGF-independent manner, but the exact nature of its role in breast cancer is not clear. IGFBP-2 contains an arginine-glycine-aspartic (RGD) integrin-recognition sequence near its C-terminus. Accordingly, the biological effects of this protein are reported to be mediated by its ability to bind to integrin receptors such integrin-α5β1, thereby facilitating activation of downstream signaling pathways (9,10). Our previous work has demonstrated that adipocytes surrounding breast cancer cells may secrete IGFBP-2 and promote breast cancer metastasis (11). We have also found that IGFBP-2 expression was elevated in both cancer cells and adipocytes in patients presenting with metastatic breast disease. In this study, we have designed an adeno-associated virus (AAV) construct containing a small interfering RNA to IGFBP-2 to examine the function of this protein in MDA-MB-468 cells. These cells are a model of...
triple-negative (ER/PR/HER2) breast cancer and have high basal levels of IGFBP-2 expression.

AAVs are attractive candidates for the creation of viral vectors for gene therapy, as these viruses are non-pathogenic and less immunogenic compared to other gene therapy vectors (12-15). AAVs are non-enveloped paroviruses that measure approximately 22 nm in diameter and have been used in many clinical trials for cancer treatment (16). In addition, Alam et al have found that although AAV2 is capable of infecting normal human mammary epithelial cells (nHMECs), it is unable to express Rep proteins or undergo active replication in this cell type (17). Therefore, AAV2 maybe a useful candidate for breast cancer gene therapy. Moreover, Alam et al have also found that infection with wild-type adenov-associated virus type 2 (AAV2) inhibited proliferation of breast cancer cell lines representing both weakly (MCF-7 and MDA-MB-468) and highly invasive (MDA-MB-231) cancer types (17). Therefore, the present study evaluated the effects of a recombinant AAV2(rAAV2) encoding an shRNA to human IGFBP-2 (rAAV2-shRNA-hIGFBP-2) on phenotypes of MDA-MB-468 breast cancer cells. We show that administration of rAAV2-shRNA-hIGFBP-2 resulted in down-regulation of IGFBP-2 in vitro and inhibited MDA-MB-468 breast cancer cell proliferation. Since paclitaxel is a commonly used drug to treat human breast cancer patients with metastasis and the drug resistance has limited its use, our tests show that rAAV2-shRNA-hIGFBP-2 could enhance the effect of paclitaxel at the same concentration. We also demonstrate that MCF10A cells are resistant to rAAV2-shRNA-scramble infection and in vivo injection of rAAV2-shRNA-hIGFBP-2 inhibits the growth of tumor xenografts derived from MDA-MB-468 cells. Finally, we show that rAAV2-shRNA-hIGFBP-2 can reduce the invasive potential of MDA-MB-468 cells to some extent.

In breast cancer, autocrine or paracrine IGFBP-2 signaling may be an important event during metastasis and drug resistance (18), thereby making this molecule an attractive target for therapeutic intervention. To this end, the present study seeks to improve the clinical feasibility of therapies that target IGFBP-2 using a relatively safe viral vector: Adeno-associated virus 2.

Materials and methods

Ethics statement. The study was approved by the institutional review board (CWO) of Medical School of Nanjing University (Nanjing, China). All experimental procedures were conducted in conformity with institutional guidelines for the care and use of laboratory animals.

Cell culture and infection with recombinant AAV2. The adenoviral packaging 293T/17 cell line (ATCC®CRL-11268), as well as the MCF-7 (ATCC®HTB-22), SKBR-3 (ATCC®HTB-30), MDA-MB-231 (ATCC®HTB-26) and MDA-MB-468 (ATCC® #132) human breast cancer cell lines originated from the American Type Culture Collection (ATCC, Manassas, VA, USA). MCF-10A cells were purchased from Shanghai Baili Biotechnology Ltd (Baili, Shanghai, China). MDA-MB-468 cells were maintained in Leibovitz's L-15 medium (GIBCO) and the remaining cell lines were maintained in high-glucose Dulbecco's Modified Eagle Medium (DMEM, GIBCO) supplemented with 110 mg/l sodium pyruvate, 2 mg/l pyridoxine hydrochloride, 2 g/l sodium bicarbonate, 10% FBS, penicillin (100 U/ml) and streptomycin (100 mg/ml). All cell cultures were maintained at 37°C in 5% CO₂. MDA-MB-468 cells were grown to approximately 80% confluence before infection with adenovirus. Specifically, culture medium was aspirated from the plates, and infections were conducted using rAAV2-ZsGreen-shRNA-scramble or rAAV2-ZsGreen-shRNA-hIGFBP2 (our laboratory cooperated with Shenzhen Biowit Technologies Company) in serum-free L-15 medium at an optimized concentration of 1.5x10¹ⁱ viral genomes/ml (vg/ml). Mock infections were also performed using only serum-free L-15 medium. Plates were incubated at 37°C for 12 h with intermittent agitation. At the end of the incubation, residual medium was aspirated from the plates and replaced with fresh L-15 medium supplemented with 10% serum. Infected cells were then stimulated with paclitaxel or IGFBP-2 on the fourth day after infection, and total RNA or protein were collected at this time. Fluorescent micro-graphs were also obtained at this time point using a Nikon TE 2000 microscope (magnification x100) to confirm infection efficiency.

Preparation of AAV2-ZsGreen virus carrying short hairpinRNA targeting human IGFBP-2. The pAAV-ZsGreen-shRNA plasmid was supplied by Biowit Technologies (Shenzhen, China). The 68 bp shRNA template sequences were designed and synthesized as follows: hIGFBP2-F: 5’-GATCCGGGACGAGTTGACAGAATTTCAAGAGAATTGTCTGCAACCTGCTCTTTTATAGTC TA-3’; hIGFBP2-R: 5’-AGCTTAGATCTAAAAAGGGACGAGTTGACAGAATTGTCTGCAACCTGCTCTTTTATAGTC TA-3’; hIGFBP2-F: 5’-GATCCGGGACGAGTTGACAGAATTTCAAGAGAATTGTCTGCAACCTGCTCTTTTATAGTC TA-3’; hIGFBP2-F: 5’-GATCCGGGACGAGTTGACAGAATTTCAAGAGAATTGTCTGCAACCTGCTCTTTTATAGTC TA-3’. BamHI and HindIII restriction sites downstream of the hU6 promoter in the pAAV-ZsGreen-shRNA vector. The final recombinant plasmids were named, ‘pAAV-ZsGreen-shRNA-hIGFBP2’ and ‘pAAV-ZsGreen-shRNA-scramble,’ and were verified by restriction enzyme digestion and sequencing at Shanghai SANGON Biological Engineering Technology and Service Co, Ltd. Adenoviral packaging 293T/17 cells were transfected with pAAV-ZsGreen-shRNA-hIGFBP2 or pAAV-ZsGreen-shRNA-scramble together with pAAV-RC and pAAV-Helpervia modified calcium phosphate co-precipitation when cell monolayers were 50-60% confluent. The cells were harvested after 72 h of transfection, and re-suspended in cell lysis buffer (10 mM Tris-HCl, pH 8.5, 150 mM NaCl). Next, the cells were frozen and thawed three times in liquid nitrogen and at 37°C, respectively. The lysate was then centrifuged at 4,000 x g for 10 min, and the supernatant was collected. Next, solid NaCl and PEG-8000
were added to the supernatant to final concentrations of 1 M and 10% (w/v), respectively, and the mixture was agitated to dissolve these components during a 1 h incubation on ice. After a 15 min centrifugation at 9,000 x g, the pellet was mixed with 1.38 g/ml of CsCl and centrifuged at 500,000 x g for 24 h at 4°C to isolate the rAAV2-ZsGreen-shRNA viral particles. Determination of viral titer was performed via qPCR amplification for purified rAAV2 and was calculated at 5x10^{11} vg/ml.

**MTT assay.** MDA-MB-231 and MCF-7 cells were cultured in 96-well plates and were serum-starved for 24 h when they reached 70% confluence. Next, culture medium with 5% FBS was added to the cells, supplemented with either 50 µM paclitaxel alone, or both 50 µM paclitaxel and 100 ng/ml IGFBP-2. To avoid attenuation the effect of IGFBP-2, cells were treated with IGFBP-2 a second time 24 h after the initial exposure. Cell viability was then determined both 48 and 72 h following drug treatment using the3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) assay (Sigma). Briefly, the cells were incubated with a 0.5% MTT solution (diluted in culture medium) for 4 h. Then 100 µl of a 0.04 M dimethylsulfoxide solution were added to each well, followed by incubation at 37°C for an additional 4 h. The absorbance of the reaction product was measured at 570 nm and is proportional to cell viability. The data were expressed as the mean ± S.D. and were used to generate growth curves. Each treatment group was assayed in triplicate.

**Trypan blue cell counting.** After infection with 1.5x10^{11} vg/ml rAAV2-ZsGreen-shRNA-scramble or AAV2-ZsGreen-shRNA-hIGFBP-2 for four days, MDA-MB-468 cells were switched to growth medium containing 5% serum and were treated with paclitaxel or vehicle control for 24 h. For each experiment, all treatments were performed in triplicate, and each experiment was repeated at least three times. Both attached and floating cells were collected by centrifugation and were stained with 0.04% Trypan blue. The number of viable and non-viable cells was quantified with a hemocytometer, and dead cells were divided by all cell counts (18).

**Cell invasion assays.** After infection with 1.5x10^{11} vg/ml rAAV2-ZsGreen-shRNA-scramble or rAAV2-ZsGreen-shRNA-hIGFBP-2 for 4 days, or stimulation with 100 ng/ml IGFBP-2 for 24 h alone, MDA-MB-468 cells were trypsinized and re-suspended in serum-free culture medium. The upper chambers of Transwell inserts (8.0 µm membrane pores, Costar, USA) were subsequently coated with 2.5 mg/ml Matrigel (LOT: 356234, BD Biosciences, USA) and incubated at 37°C for 30 min. A total of 10^5 cells in 200 µl of medium were then added to the upper chambers of the inserts and were allowed to migrate toward the bottom chambers, which contained medium with 20% FBS as a chemoattractant. After 24 h, the cells on the apical surfaces of the membranes were removed using a cotton swab, and cells on the underside were fixed in 3.7% paraformaldehyde (PFA) and stained with crystal violet. Quantification of migrated cells was performed by dissolving crystal violet with 10% acetic acid, and the optical density of each sample was read with a micro-plate reader at 595 nm. Phase contrast micro-graphs were also obtained at a magnification of x100. Experiments were performed with technical duplicates and were repeated at least three times with consistent results.

**Western blotting and immunohistochemistry.** When MDA-MB-231, MDA-MB-468, MCF-7 and SKBR-3 cells reached approximately 60-70% confluence in their conventional growth media, they were then switched to either serum-free medium containing 100 ng/ml IGFBP-2, or serum-free medium alone. Protein was collected after 24 h. Protein from MDA-MB-468 cells infected with AAV2 was harvested four h after infection. Western blotting was performed according to established protocols (19), and the following antibodies were used: IGFBP-2 (1:1,000, Abcam4243), ER-α (1:1,000, sc-73479), integrin-α5 (1:1,000, sc-10729), p-ErbB2 (1:1,000, CST#2241), ErbB2 (1:1,000, CST#2242) and GAPDH (1:1,000, BD Biosciences). Immunohistochemical staining was performed on 5 µm formalin-fixed, paraffin-embedded tumor tissue sections. Tissue sections were deparaffinized in xylenes and hydrated in a graded sequence of ethanol solutions. For antigen retrieval, sections were then heated in a microwave in citrate buffer (pH 6.0). After cooling, nonspecific binding was blocked with diluted serum (5% bovine serum albumin) followed by incubation with antibodies against CK-7 (1:500, Abcam 183344), IGFBP-2 (1:300, Abcam 109284), MMP-2 (1:500, Abcam 1818) and Ki67 (1:1,000, Abcam 92742) at room temperature in a humidified chamber for 2 h. Negative control sections incubated without primary antibodies were also used. After incubation with primary antibodies, sections were washed with phosphate-buffered saline (PBS) and subsequently treated using the corresponding biotinylated secondary antibody from an Ultrasview ONE kit (Thermo Fisher Scientific, USA) according to the manufacturer's protocol. Peroxidase activity was visualized using 3,3'-diaminobenzidine, and sections were counterstained with hematoxylin.

**Detection of IGFBP-2 gene expression.** MDA-MB-231, MDA-MB-468, MCF-7 and SKBR-3 cells were stimulated with 100 ng/ml IGFBP-2 for 24 h in serum-free medium, and total cell RNA was extracted using TRizol reagent (Invitrogen) according to the manufacturer's instructions. Total viral RNA from infected MDA-MB-468 and MCF-10A cells was also extracted. RNA yields were measured using a NanoDrop D-2000 (Thermo Fisher Scientific, USA) instrument. First-strand cDNA was then synthesized from 1 µg total RNA using oligo-dT primers and the SuperScript II Reverse Transcriptase kit (Invitrogen), according to the manufacturer's instructions. Quantitative real-time PCR was performed in 20 µl reaction mixtures containing 1 µl of the cDNA preparation, 10 µl 2X SYBR Green Premix Ex Taq (Takara, DRR041S), and 1 µM primer pairs on an ABI Step One PCR Instrument. The primer sequences used for IGFBP-2 amplification were R: 5'-GTC TCT GAT CTC CCG TGG GTT-3; F: 5'-GCA ACG GGT GCA AAG CTC ATC-3, and the primer sequences used for GAPDH amplification were R: 5'-GGA AGT AGG TGT GGG ATT T-3; F: 5'-AAC GAT TGG TGT GCT AT T-3. The thermal profile for the real-time PCR reaction consisted of 5 min at 95°C followed by 40 cycles of 30 sec at 95°C and 1 min at 60°C. Each sample was assayed in triplicate. Threshold values were determined for each sample/primer pair, and the average and standard error of gene expression were calculated. The specificity of the PCR products was then verified by melt curve analysis.
analysis, and products from each reaction were electrophoresed on a 1.8% agarose gel. GAPDH was used as an internal standard for mRNA expression.

**rAAV2-ZsGreen-shRNA-hIGFBP-2 in breast cancer hypodermic model.** The effect of rAAV2-ZsGreen-shRNA-hIGFBP-2 on breast tumor growth was determined using the athymic mouse model of breast cancer by hypodermic injection. Female BALB/c nude mice used in this study (4-5 weeks old and weighing 20.0±2.0 g) were obtained from the Changzhou Vinc Experimental Animal Co. Ltd (Qualification certificate numbers: 201505694 and 201508683) and were housed in a defined pathogen-free environment. All procedures were approved by the National Animal Care and Use Committee in China and the Laboratory Animal Center of the Academy of Medical Sciences of Nanjing University. Briefly, MDA-MB-468 cells were trypsinized and washed with serum-free L-15 medium three times to remove residual enzyme. Next, mice were anesthetized via inhalation of isoflurane, and 10^5 MDA-MB-468 cells in 100 μl of a mixture consisting of 50 μl complete medium and 50 μl Matrigel (BD, 356234) were injected subcutaneously into the left flank. After the tumor volume reached approximately 75 mm^3 (around the 15th day post-injection), AAV2-ZsGreen-shRNA-hIGFBP-2 or scramble viral particles (1.0x10^8 vg/ml in PBS) were administered by direct injection into the xenograft (4 sites/lump, 25 μl/site) using a syringe with a 30-gauge needle every five days for 30 days. A control group of mice received intratumoral injections of PBS in parallel with the treatment groups. Tumor dimensions were measured with vernier calipers every five days beginning at the 15th day post-injection by euthanizing three mice and excising their tumors. Tumor volumes were calculated using the following formula: volume (V) = L x W^2 x π/6, where L is the length and W is the width of the tumor. For histological analysis, subcutaneous tumors were excised and fixed in 4% paraformaldehyde for 12 h and embedded in paraffin. Additionally, frozen tumor tissue was embedded in optimal cutting temperature (OCT) compound, and sectioned into 6 μm sections with a freezing microtome. The infection efficiency of in vivo viral gene transfer was assessed in cryosectioned tumor tissue using fluorescence microscopy (wave length 488 nm).

**Statistical analysis.** Results are expressed as means ± standard deviation (SD). Differences between the groups were determined with the Student’s t-test. All analyses were performed with SPSS software (IBM, USA), version 10.0. Differences among groups were considered to be significantly different at P<0.05.

**Results**

**IGFBP-2 promoted survival and impacted chemosensitivity of breast cancer cells.** Exogenous addition of IGFBP-2 increased the protein-level expression of IGFBP-2 and integrin-α5β1 in MDA-MB-231, MDA-MB-468, MCF-7 and SKBR-3 cells, which represent different subtypes of breast cancer (Fig. 1A). Among these cell lines, the triple-negative breast cancer cell line, MDA-MB-468, exhibited the most robust levels of basal IGFBP-2 expression (Fig. 1A). In addition, exogenous IGFBP-2 (100 ng/ml) enhanced the viability of paclitaxel-treated MDA-MB-231 and MCF-7 cells (Fig. 1B and C), although no further increases in survival were observed when the dose of IGFBP-2 was increased to 500 ng/ml. Moreover, IGFBP-2 was down-regulated on the fourth day after infection with rAAV2-ZsGreen-shRNA-hIGFBP-2. By the fifth day after infection, loss of IGFBP-2 significantly increased the number of dead MDA-MB-468 cells compared to control cells infected with rAAV2-ZsGreen-shRNA-scrumble. With respect to chemosensitivity, MDA-MB-468 cells infected with rAAV2-ZsGreen-shRNA-hIGFBP-2 exhibited a greater paclitaxel sensitivity compared to cells infected with rAAV2-ZsGreen-shRNA-scrumble. Indeed, the number of dead cells infected with rAAV2-ZsGreen-shRNA-hIGFBP-2 increased to 56% of the total cell population, a 1.9-fold increase over the scramble control (Fig. 1D).

**rAAV2-ZsGreen-shRNAs did not infect normal human mammary epithelial cells MCF-10A.** MDA-MB-468 and MCF-10A cells were infected with rAAV2-ZsGreen-shRNA-scrumble or rAAV2-ZsGreen-shRNA-hIGFBP-2 at the same viral titers. On the fourth day post-infection, MDA-MB-468 cells exhibited robust green fluorescence, while MCF-10A cells were only weakly fluorescent (Fig. 2A). In addition, MDA-MB-468 cells infected with rAAV2-ZsGreen-shRNA exhibited reduced proliferation, which eventually culminated in apoptosis. These responses were not observed in MCF-10A cells (data not shown). Next, IGFBP-2 expression in MDA-MB-468 but not MCF-10A cells was demonstrated to be down-regulated at both the mRNA and protein levels following infection with rAAV2-ZsGreen-shRNA-hIGFBP-2 (Fig. 2B and C). These results suggest that AAV2 can specifically targeting breast cancer cells, but not normal mammary epithelial cells.

**rAAV2-ZsGreen-shRNA inhibited proliferation of MDA-MB-468 cells in vivo.** We next asked if direct injection of rAAV2-ZsGreen-shRNA into tumor xenografts could inhibit their growth in vivo. To this end, we injected a mixture of MDA-MB-468 cells and Matrigel into the mammary fat pads of nude mice. Fifteen days or 45 days after injection, the mice were euthanized and the tumors were excised (Fig. 3A). Hematoxylin and eosin (H&E) staining was then performed to verify the morphology of the tumor cells. We also used frozen tissue sections to confirm that the viruses had successfully targeted the tumor cells (Fig. 3B). With respect to tumor volume, tumors injected with rAAV2-ZsGreen-shRNA-scrumble and rAAV2-ZsGreen-shRNA-hIGFBP-2 both exhibited significantly reduced primary tumor volume compared to control tumors injected with PBS (Fig. 3C), but rAAV2-ZsGreen-shRNA-hIGFBP-2 had more marked effect. In addition, immunohistochemical staining revealed that injection of rAAV2-ZsGreen-shRNA-scrumble and rAAV2-ZsGreen-shRNA-hIGFBP-2 both decreased tumor Ki-67 expression (Fig. 3D). A general post mortem examination revealed no obvious organ-specific toxicity in any of the virus-treated animals.
rAAV2-ZsGreen-shRNA-IGFBP-2 suppressed the invasive potential of MDA-MB-468 cells. While IGFBP-2-stimulated MDA-MB-468 cells showed markedly enhanced invasion potential, rAAV2-ZsGreen-shRNA-hIGFBP-2-infected MDA-MB-468 cells showed markedly enhanced invasion potential. While IGFBP-2-stimulated MDA-MB-468 cells showed markedly enhanced invasion potential, rAAV2-ZsGreen-shRNA-hIGFBP-2-infected MDA-MB-468 cells showed markedly enhanced invasion potential. While IGFBP-2-stimulated MDA-MB-468 cells showed markedly enhanced invasion potential, rAAV2-ZsGreen-shRNA-hIGFBP-2-infected MDA-MB-468 cells showed markedly enhanced invasion potential.
cells showed impaired invasion potential compared to control cells infected with rAAV2-ZsGreen-shRNA-scramble (Fig. 4A). These results were quantified by dissolving crystal violet with a micro-plate reader (Fig. 4B). Moreover, mouse tumors injected with rAAV2-ZsGreen-shRNA-hIGFBP-2 exhibited markedly reduced MMP-2 expression compared to tumors injected with either PBS or rAAV2-ZsGreen-shRNA-scramble (Fig. 4C).

Discussion

Breast cancer is the most common cancer type in women and is associated with a high mortality rate due to the propensity of this disease to metastasize. Personalized treatment is often recommended based on histological sub-types characterized by the expression of estrogen (ER), progesterone (PR) and Her-2 receptors. Importantly, patients with triple-negative (ER/PR/HER2-) breast cancer are often faced with the worst prognosis. Previous work has shown that IGFBP-2 can stimulate the proliferation of a number of different cell types, including prostate cancer cells (20), glioma (21), and chondrocytes (22). Our previous work has also found that IGFBP-2 is secreted into the breast cancer micro environment by adipocytes, where it promotes cancer metastasis. In this study, we attempted to clarify further the effects of IGFBP-2 in breast cancer cells and establish its role as a putative therapeutic target. This hypothesis further supported by the observation that exogenous IGFBP-2 could promote survival of MDA-MB-231 and MCF-7 breast cancer cells in the presence of paclitaxel, while loss of IGFBP-2 enhanced the chemosensitivity of MDA-MB-468 cells. We had tried doxorubicin to do the same tests in Fig. 1 but there was not significant difference between different treatments.

IGFBP-2 possesses Arg-Gly-Asp integrin-binding motifs and is among the many proteins that interact with integrin-α5β1. This interaction has been reported to be involved in modulating the effects of IGFBP-2 on glioma cell migration and invasion (23). In our study, exogenous IGFBP-2 could promote the protein-level expression of integrin-α5β1 in four breast cancer cell lines. We also found that exogenous IGFBP-2 up-regulated the expression of endogenous IGFBP-2 in our panel of breast cancer cell lines. Similarly, in a study by Sehgal et al, IGFBP-2 was shown to up-regulate β-catenin expression in breast cancer cells, which then further enhanced IGFBP-2 expression via a positive-feedback mechanism (24). Therefore, suppressing the effects of IGFBP-2 may help to impede breast cancer progression.

Among the cell lines tested, the highly metastatic, triple-negative breast cancer cell line, MDA-MB-231, exhibited the most significant increase in IGFBP-2 expression. Moreover, MDA-MB-468 cells exhibit abundant levels of basal IGFBP-2 expression, this cell type represents a favorable breast cancer model in which to test the effects of rAAV2-shRNA-hIGFBP-2 treatment in vitro and in vivo. In our in vitro study, infection of MDA-MB-468 cells with rAAV2-ZsGreen-shRNA-hIGFBP-2
led to IGFBP-2 down-regulation, increased cell death and enhanced chemosensitivity to paclitaxel compared to infection with rAAV2-ZsGreen-shRNA-scramble. These results supported the notion that rAAV2-ZsGreen-shRNA-hIGFBP-2 may have therapeutic effects on triple-negative breast cancer cells. Moreover, the inability of AAV2 to infect normal mammary epithelial (MCF-10A) cells renders the potential clinical applications of this therapy even more exciting. Actually...
AAV2 transfection efficiency was strong in a certain number of breast cancer lines which are not confined to TNBC. We can see evidence based on southern blot analysis that MCF-7 cells with ER(+) can also be transfected with AAV2 in reference (17). In contrast, neither the 4.7 kb replicative form DNA monomer nor the Rep protein expression could be detected in nHMECs. To our knowledge, AAV2 transfection efficiency was strong in human breast cancer cell line MCF-7, MDA-MB-468, MDA-MB-231 and MDA-MB-435. We hope this virus which can not reproduce in normal human epithelial cells may attribute to future clinical therapy of human breast cancer. We speculate that this virus could not replicate in MCF-10A cells because AAV2-encoded Rep proteins may be inhibited by certain factors present in normal mammary epithelial cells.

The clinical application of small interfering RNA (siRNA)-based therapy is limited by the poor stability, poor intracellular uptake, and rapid enzymatic degradation of these molecules. To overcome these limitations, we used adeno-associated virus type 2 (AAV2) to deliver siRNAs to cancer cells. Importantly, this method is non-pathogenic, and these viruses do not infect normal human mammary epithelial cells. Several lines of evidence suggest that over-expression of IGFBP-2 increases cell growth and metastatic potential in several tumor types, including ovarian (25), prostate (26), and bladder cancer (27), as well as glioblastoma (28). Based on the results of our study, we expect that recombinant AAV2-ZsGreen-shRNA-hIGFBP-2 can inhibit the proliferation of tumor xenografts derived from MDA-MB-468 cells more significantly.

Furthermore, the rAAV2-ZsGreen-shRNA-hIGFBP-2-infected MDA-MB-468 cells exhibited reduced invasive potential in vitro, whereas exogenous IGFBP-2-stimulated MDA-MB-468 invasion. Taken together, these results further suggest that this recombinant virus maybe a useful tool for preventing metastasis in breast cancer patients. Importantly, our previous work has demonstrated that exogenous IGFBP-2 could enhance the expression of MMP-2 in breast cancer cells (11). Therefore, this result is in accord with the trans-well assay and indicates that rAAV2-ZsGreen-shRNA-hIGFBP-2 maybe used to impede tumor metastasis in breast cancer patients. Taken together, our in vitro and in vivo results indicate that rAAV2-ZsGreen-shRNA-hIGFBP-2 can inhibit the growth of MDA-MB-468 cells, as well as enhance chemosensitivity and reduce invasive potential in this cell type.
In conclusion, we have constructed an AAV-2-mediated siRNA delivery system designed to target IGFBP-2-regulated pathways in breast cancer. The effectiveness of this system in both in vitro and in vivo models has been reported for the first time in the present study. We show that MCF10A cells are resistant to rAAV2-shRNA-scramble infection and in vivo injection of rAAV2-shRNA-hIGFBP2 inhibits the growth of tumor xenografts derived from MDA-MB-468 cells. We also demonstrate that rAAV2-shRNA-hIGFBP2 can reduce the invasive potential of MDA-MB-468 cells in vitro.

Acknowledgements

This article is supported by the Jiangsu Natural Science Foundation of China (grant no. BK20130591). The authors would like to thank the company Biowit Technologies (Shenzhen, China).

References

1. el Atiq F, Garrouste F, Remacle-Bonnet M, Sastre B and Pommier G: Alterations in serum levels of insulin-like growth factors associated with insulin-like growth-factor-binding proteins in patients with colorectal cancer. Int J Cancer 57: 491-497, 1994.

2. Karasik A, Menczer J, Pariente C and Kanety H: Insulin-like growth factor-1 (IGF-1) and IGF-binding protein-2 are increased in cyst fluids of epithelial ovarian cancer. J Clin Endocrinol Metab 78: 271-276, 1994.

3. Baron-Hay S, Boyle F, Ferrier A and Scott C: Elevated serum insulin-like growth factor binding protein 2 as a prognostic marker in patients with ovarian cancer. Clin Cancer Res 10: 1796-1806, 2004.

4. Lee DY, Kim SJ and Lee YC: Serum insulin-like growth factor (IGF)-I and IGF-binding proteins in lung cancer patients. J Kor Med Sci 14: 401-404, 1999.

5. Cohen P, Peehl DM, Stamey TA, Wilson KF, Clemmons DR and Rosenfeld RG: Elevated levels of insulin-like growth factor binding protein-2 and -3 with prostate cancer invasion, progression and metastasis. J Clin Oncol 20: 833-841, 2002.

6. Shariat SF, Lamb DJ, Kattan MW, Nguyen C, Kim J, Beck J, Wheeler TM and Slawin KM: Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression and metastasis. J Clin Oncol 20: 833-841, 2002.

7. Busund LT, Richardsen B, Busund R, Ukkonen T, Bjørnsen T, Busch C and Stalsberg H: Significant expression of IGFBP2 in breast cancer compared with benign lesions. J Clin Pathol 58: 361-366, 2005.

8. So AI, Levitt RI, Eigl B, Fazli L, Muramaki M, Leung S, Chang MC, Nielsen TO, Gleave M and Pollak M: Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancer. Clin Cancer Res 14: 6944-6954, 2008.

9. Schütt BS, Langkamp M, Rauschnebel U, Ranke MB and Emlinger MW: Integrin-mediated action of insulin-like growth factor binding protein-2 in tumor cells. J Mol Endocrinol 32: 859-868, 2004.

10. Pereira JJ, Meyer T, Docherty SE, Reid HH, Marshall J, Thompson EW, Rossjohn J and Price JT: Bimolecular interaction of insulin-like growth factor with alphavbeta3 negatively modulates IGF-I-mediated migration and tumor growth. Cancer Res 64: 977-984, 2004.

11. Wang C, Gao C, Meng K, Qiao H and Wang Y: Human adipocytes stimulate invasion of breast cancer MCF-7 cells by secreting IGFBP-2. PLoS One 10: e0119348, 2015.

12. Zannis AK and Muruve DA: Immunity to adeno-associated virus vectors in animals and humans: A continued challenge. Gene Therapy 15: 808-816, 2008.

13. Herzog RW, Yang EY, Couto LB, Hagstrom JN, Elwell ID, Fields PA, Burton M, Bellinger DA, Read MS, Brinkhous KM, et al: Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med 5: 56-63, 1999.

14. Wang L, Takabe K, Biddlemaier SM, III CR and Verma IM: Sustained correction of bleeding disorder in hemophilia B mice by gene therapy. Proc Natl Acad Sci USA 96: 3906-3910, 1999.

15. Ponnazhagan S, Mahendra G, Kumar S, Shaw DR, Stockard CR, Grizzle WE and Meleth S: Adeno-associated virus 2-mediated antiangiogenic cancer gene therapy: Long-term efficacy of vector encoding angiostatin and endostatin over vectors encoding a single factor. Cancer Res 64: 1781-1787, 2004.

16. Collins SA, Buhles A, Scallen MF, Harrison PT, O’Hanlon DM, O’Sullivan GC and Tangey M: AAV2-mediated in vivo immune gene therapy of solid tumours. Gene Vaccines Ther 8: 8, 2010.

17. Alam S, Bowser BS, Conway MJ, Israr M, Tandon A and Meyers C: Adeno-associated virus type 2 infection activates caspase dependent and independent apoptosis in multiple breast cancer lines but not in normal mammary epithelial cells. Mol Cancer 10: 97, 2011.

18. Foulstone EJ, Zeng L, Perks CM and Holly JM: Insulin-like growth factor binding protein 2 (IGFBP-2) promotes growth and survival of breast epithelial cells: Novel regulation of the estrogen receptor. Endocrinology 154: 1780-1793, 2013.

19. Wang C, Bian Z, Wei D and Zhang JG: MiR-29b regulates migration of human breast cancer cells. Mol Cell Biochem 352: 197-207, 2011.

20. Uzoechi C, Holly JM, Biernacka KM, Persad RA, Bahl A, Gillatt D and Perks CM: Insulin-like growth factor-binding protein-2 promotes prostate cancer cell growth via IGF-dependent and -independent mechanisms and reduces the efficacy of docetaxel. Br J Cancer 104: 1587-1593, 2011.

21. Holmes KM, Annala M, Chua CY, Dunlap SM, Liu Y, Hugen N, Menz LM, Cogdell D, Nykter M, et al: Insulin-like growth factor-binding protein-2 driven glioma progression is prevented by blocking a clinically significant integrin, integrin-linked kinase, and NF-kB network. Proc Natl Acad Sci USA 109: 3475-3480, 2012.

22. Kiepe D, Van Der A, Ciarmatori S, Ständker L, Schütt B, Hoeflich A, Hügel U, Oh J and Tönshoff B: Defined carboxy-terminal fragments of insulin-like growth factor (IGF) binding protein-2 exert similar mitogenic activity on cultured rat growth plate chondrocytes as IGF-1. Endocrinology 149: 4901-4911, 2008.

23. Wang GK, Hu L, Fuller GN and Zhang W: An interaction between insulin-like growth factor-binding protein 2 (IGFBP2) and integrin alpha5 is essential for IGFBP2-induced cell mobility. J Biol Chem 281: 14088-14091, 2006.

24. Sehgal P, Kumar N, Praveen Kumar VR, Patil S, Bhattacharya A, Wijaya Kumar M, Mukherjee G and Kondaiah P: Regulation of protumorigenic pathways by insulin like growth factor binding protein2 and its association along with beta-catenin in breast cancer lymph node metastasis. Mol Cancer 12: 63, 2013.

25. Chakrabarty S and Kondratlick E: Insulin-like growth factor binding protein-2 stimulates proliferation and activates multiple cascades of the mitogen-activated protein kinase pathways in NIH-OVCA3 human epithelial ovarian cancer cells. Cancer Biol Ther 5: 189-197, 2006.

26. Chatterjee S, Park EJ, Park JS, Lee RJ, Kim HK and Cho YS: Regulation of proliferation by EGF in colorectal cancer cells is inhibited by suppressing insulin-like growth factor binding protein-2. Cell Growth & Differentiation 16: 483-489, 2005.

27. Miyake H, Hara I, Yamamaka K, Muramaki M, Gleave M and Eto H: Introduction of insulin-like growth factor binding protein-2 gene into human bladder cancer cells enhances their metastatic potential. Mol Cancer 13: 341-345, 2005.

28. Fukushima T, Tezuka T, Shimomura T, Nakano S and Kataoka H: Silencing of insulin-like growth factor-binding protein-2 in human glioblastoma cells reduces both invasiveness and expression of glioma-associated integrin subunits in glioblastoma. Oncol Rep 18: 643-649, 2007.